Related Experiment Video
Updated: Jan 22, 2026
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
2.3K
IgA Nephropathy in Elderly Patients
Angel M Sevillano1,2, Monserrat Diaz3, Fernando Caravaca-Fontán1,2
1Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Summary
The diagnosis of IgA nephropathy is increasing in older adults. This kidney disease has a poor prognosis in this population, with acute kidney injury being a common presentation.
Area of Science:
- Nephrology
- Epidemiology
- Geriatric Medicine
Background:
- Increasing incidence of IgA nephropathy (IgAN) in older adults.
- Limited data on IgAN epidemiology and clinical behavior in this demographic.
Purpose of the Study:
- To analyze the incidence, presentation, characteristics, treatment, and outcomes of IgAN in patients aged 65 and older.
- To identify risk factors and prognostic indicators for IgAN in the elderly.
Main Methods:
- Retrospective, multicenter study of 151 patients (≥65 years) with biopsy-proven IgAN.
- Data collected from 1990 to 2015, focusing on incidence, clinical/histologic features, treatments, and outcomes.
- Primary outcome: kidney replacement therapy or death.
Main Results:
- Significant increase in IgAN diagnoses over time (P=0.03).
- Acute kidney injury (AKI) was the most common presentation (40%), often hematuria-related.
- Poor survival rates: 74% at 1 year, 48% at 2 years, 26% at 5 years.
- Oral anticoagulant use was common in AKI patients.
Conclusions:
- IgAN diagnosis is rising in older Spanish adults, potentially linked to anticoagulant use.
- IgAN in older adults has a poor prognosis.
- Age, creatinine, and interstitial fibrosis are risk factors; RAAS blockers showed benefit.
Keywords:
AngiotensinsAnticoagulantsBiopsyErythrocytesGlomerulonephritis, IGAHematuriaIgA nephropathyIncidenceKidney Function TestsPrognosisRenal Replacement TherapyReninRetrospective Studiesacute kidney injuryacute renal failurealdosteroneanticoagulation therapycreatininehematurianephrotic syndromerisk factors
Related Concept Videos
01:13Patient-centered Care
2.9K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
2.9K
01:21Drug Dosing: Obese Patients
235
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
235
01:15Drug Dosing: Geriatric Patients
229
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
269
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
269
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
198
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
198
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
192
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
192